StockNews.AI
REPL
StockNews.AI
27 days

Rosen Law Firm Encourages Replimune Group, Inc. Investors to Inquire About Securities Class Action Investigation - REPL

1. Rosen Law Firm investigates Replimune for potentially misleading business information. 2. Shareholders may recover losses through a class action lawsuit. 3. Replimune stock fell 77% following FDA's Complete Response Letter for RP1. 4. The FDA deemed the IGNYTE trial insufficient for RP1 approval. 5. Rosen Law Firm has a successful track record in securities class actions.

6m saved
Insight
Article

FAQ

Why Very Bearish?

Replimune's stock plummeted over 77% due to an unfavorable FDA decision, indicating severe investor sentiment decline. Historically, such drastic share price drops often lead to extensive legal and financial repercussions, further tampering investor confidence.

How important is it?

The article details a significant legal issue affecting Replimune which is likely to impact stock prices and investor sentiment significantly. The company's future, given the FDA's decision and the ensuing investigation, raises essential questions about its viability and credibility.

Why Short Term?

The immediate effect is seen with the drastic stock drop and pending litigation, which could create volatility over the coming weeks. If the class action lawsuit progresses, further uncertainty could affect stock performance in the short term.

Related Companies

REGNMRNAAMGN
, /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Replimune Group, Inc. (NASDAQ: REPL) resulting from allegations that Replimune may have issued materially misleading business information to the investing public. So What: If you purchased Replimune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=42313 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. What is this about: On July 22, 2025, before the market opened, Replimune issued a press release entitled "Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma." The press release stated that Replimune had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma." The press release stated that the CRL "indicates that the FDA is unable to approve the application in its present form. The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness." On this news, Replimune common stock fell $9.52 per share, or over 77%, to close at $2.80 on July 22, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq.Phillip Kim, Esq.The Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827[email protected]www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News